Business Description
Zelira Therapeutics Ltd
NAICS : 212221
ISIN : AU000000ZLD1
Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | -0.87 | |||||
| Debt-to-Equity | -1.32 | |||||
| Debt-to-EBITDA | -0.17 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -45.05 | |||||
| Beneish M-Score | -593.96 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -50.3 | |||||
| 3-Year EBITDA Growth Rate | -37.2 | |||||
| 3-Year EPS without NRI Growth Rate | 27.3 | |||||
| 3-Year FCF Growth Rate | 33.2 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.06 | |||||
| 9-Day RSI | 32.29 | |||||
| 14-Day RSI | 37.04 | |||||
| 6-1 Month Momentum % | 69.27 | |||||
| 12-1 Month Momentum % | -26.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.6 | |||||
| Quick Ratio | 0.42 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 6050.02 | |||||
| Days Sales Outstanding | 876 | |||||
| Days Payable | 12512.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -67.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 11.58 | |||||
| Operating Margin % | -6250.53 | |||||
| Net Margin % | -38493.68 | |||||
| FCF Margin % | -4567.19 | |||||
| ROE % | -439.78 | |||||
| ROA % | -259.34 | |||||
| ROIC % | -45.13 | |||||
| ROC (Joel Greenblatt) % | -9482 | |||||
| ROCE % | -381.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 70.55 | |||||
| EV-to-EBIT | -0.35 | |||||
| EV-to-EBITDA | -0.35 | |||||
| EV-to-Revenue | 130.2 | |||||
| EV-to-FCF | -2.93 | |||||
| Earnings Yield (Greenblatt) % | -285.71 | |||||
| FCF Yield % | -60.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zelira Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.064 | ||
| EPS (TTM) ($) | -2.156 | ||
| Beta | 2.49 | ||
| Volatility % | 205.15 | ||
| 14-Day RSI | 37.04 | ||
| 14-Day ATR ($) | 0.005358 | ||
| 20-Day SMA ($) | 0.460535 | ||
| 12-1 Month Momentum % | -26.19 | ||
| 52-Week Range ($) | 0.1912 - 0.688 | ||
| Shares Outstanding (Mil) | 11.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Zelira Therapeutics Ltd Frequently Asked Questions
What is Zelira Therapeutics Ltd(ZLDAF)'s stock price today?
The current price of ZLDAF is $0.45. The 52 week high of ZLDAF is $0.69 and 52 week low is $0.19.
When is next earnings date of Zelira Therapeutics Ltd(ZLDAF)?
The next earnings date of Zelira Therapeutics Ltd(ZLDAF) is .
Does Zelira Therapeutics Ltd(ZLDAF) pay dividends? If so, how much?
Zelira Therapeutics Ltd(ZLDAF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers